Ribomic

Ribomic Operating Expenses

The Total Operating Expenses of Ribomic (4591.T) as of Oct 30, 2026 is 1.21 B JPY. In the previous year, Total Operating Expenses was 790.99 M JPY — a change of 52.99% (higher).

Operating Expenses

1.21 BJPY

YoY

52.99%

Last updated:

Total Operating Expenses of Ribomic is 2026 1.21 B JPY. Total Operating Expenses of Ribomic was 2025 790.99 M JPY. It decreases by 52.99% higher compared to the previous year.

The Ribomic Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2019
911.29 M JPY
Jan 1, 2020
773.54 M JPY
Jan 1, 2021
1.05 B JPY
Jan 1, 2022
1.58 B JPY
Jan 1, 2023
1.60 B JPY
Jan 1, 2024
869.82 M JPY
Jan 1, 2025
790.99 M JPY
Jan 1, 2026
1.21 B JPY
The Ribomic Operating Expenses history
YEAROperating ExpensesYoY
1.21 BJPY+52.99%
790.99 MJPY-9.06%
869.82 MJPY-45.73%
1.60 BJPY+1.35%
1.58 BJPY+51.18%
1.05 BJPY+35.23%
773.54 MJPY-15.12%
911.29 MJPY-5.36%
962.91 MJPY+14.11%
843.87 MJPY+31.70%
640.73 MJPY+40.39%
456.38 MJPY+11.98%
407.55 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ribomic Stock analysis

What does Ribomic do? Ribomic, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for therapeutic applications. Headquartered in Minato-Ku, Tokyo-To, the company utilizes its workforce of 25 full-time employees to drive its drug discovery operations, which are structured into self discovery and co-discovery divisions. This operational framework allows the firm to focus on advancing RNA aptamer technologies for medical use. The Self Drug Discovery division develops aptamers and licenses these results to pharmaceutical companies, generating revenue through intellectual property transfers. Meanwhile, the Co-Discovery division collaborates with alliance pharmaceutical companies researching aptamer pharmaceuticals. This segment earns research expenses paid by the alliance partners for the shared portion of the co-discovery business, creating a dual revenue stream based on licensing and collaborative research fees. Ribomic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ribomic stock

Total Operating Expenses of Ribomic is 1.21 B JPY in 2026.

Total Operating Expenses of Ribomic changed from 790.99 M JPY to 1.21 B JPY, representing a 52.99% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses Ribomic since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's Ribomic historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Ribomic

All Key Metrics — Ribomic